Latest News

This final statement of reasons sets forth the reasons for the repeal of Section 12713 (Exposure to Foods, Drugs, Cosmetics, and Medical Devices) and the amendment to Section 12701 (General), and responds to the objections and recommendations submitted regarding these actions. 

OEHHA has provided a number of comments on the risk characterization methodology and conclusions on the draft RCD for Cycloate. These comments and our recommendations, as well as suggested clarifications, additions and corrections, are contained in this report.

OEHHA has provided a number of comments on the risk characterization methodology and conclusions on the draft RCD for Paclobutrazol. These comments and our recommendations, as well as suggested clarifications, additions and corrections, are contained in the attachment.

OEHHA has provided a number of comments on the risk characterization methodology and conclusions on the draft RCD for Abamectin. These comments and our recommendations, as well as suggested clarifications, additions and corrections, are contained in the attachment.

The purpose of this regulation is to provide "safe harbor" no significant risk levels for dichloromethane (methylene chloride), trichloroethylene, and vinyl chloride.

The purpose of this regulation is to provide "safe harbor" no significant risk levels for an additional 140 chemicals, below which the Act does not apply. 

This regulation adopts "no significant risk" levels in Section 12705, subsection (b), for the following chemicals: Arsenic, Butylated hydroxyanisole, Cadmium, and Chromium (hexavalent compounds). 

This regulation adopts "no significant risk" levels for Hexachlorodibenzodioxin (HCDD) of 0.0002 microgram per day and 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) of 0.000005 microgram per day. 

This regulation adopts no significant risk levels for Benzyl chloride of 4 micrograms per day and Bromodichloromethane of 5 micrograms per day. 

OEHHA has provided a number of comments on the risk characterization methodology and conclusions on the draft RCD for Abamectin. These comments and our recommendations, as well as suggested clarifications, additions and corrections, are contained in this report.